In April, Aetion, the Real World Evidence Platform®, partnered with HealthVerity to launch a real-time treatment tracker for COVID-19, allowing doctors and researchers to assess outcomes and how treatments are evolving. A month later, Aetion partnered with the FDA to use real-world evidence to analyze potential treatment plans. Now, Aetion is actively being used by…
CHICAGO, Sept. 2, 2020 /PRNewswire/ — The Blood Profiling Atlas in Cancer Consortium (BloodPAC) published “Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC’s Analytical Variables Working Group,” in the September 2020 issue of Clinical Chemistry. Developed by consortium members, the resource serves as set of…
Bristol Myers Squibb awarded a $5 million grant to Stand Up To Cancer for research and education efforts to achieve health equity for underserved patients with lung cancer. The 3-year grant will fund supplemental grants with a particular focus on Black populations and people living in rural communities. The effort is a part of Stand…
NEW YORK – The US Department of Health and Human Services’ decision to abruptly restrict the US Food and Drug Administration’s ability to require premarket review of laboratory-developed tests (LDTs) through guidance and other informal communications has industry players scrambling to figure out how this impacts their diagnostic regulatory strategies. Last week, HHS stated that…
The Trump administration unexpectedly announced that the FDA will no longer regulate some lab tests, including those for COVID-19. In addition to potentially allowing unreliable COVID tests on the market, the decision creates an opening for more bogus CAM tests. The U.S. Department of Health and Human Services (HHS) announced last week that the FDA…
Former FDA chief Scott Gottlieb’s favorite real-world evidence platform is getting a new stream of cash, as it nears what will likely be the biggest test of the young company so far. Aetion, the New York health tech startup, has for the second time raised an extension to their Series B, adding $19 million from…
The company provies real-world data to help organizations make better clinical decisions One of the major problems in all healthcare systems is knowing which treatments work best for which patient, and who should pay for them. That lack of knowledge results in longer treatment times, it increases the cost of care, and it leads to…
The global “COVID-19 diagnostics market size” is projected to reach USD 11.40 billion by 2027, exhibiting a CAGR of 7.9% during the forecast period. Uncontrolled spread of the coronavirus worldwide will be the major factor propelling the growth of this market, shares Fortune Business Insights™ in its report, titled “COVID-19 Diagnostics Market Size, Share &…
Overblown claims about antibodies harvested from infected Covid-19 patients’ blood threaten to undermine public faith in future FDA approvals of therapies or even vaccines. The Food and Drug Administration will release additional information to support the recent emergency use authorization on convalescent plasma to treat Covid-19, Commissioner Stephen Hahn said Tuesday on “CBS This Morning.”…
The development of complex biomarkers such as tumor mutational burden (TMB) has enabled clinicians to identify patients more likely to respond to treatment of a variety of cancers, leading to more accurate diagnoses and improved outcomes. Differences in testing assays, however, have produced inconsistent reporting in the clinical setting. For its first-ever virtual symposium, Friends…
